Atossa Therapeutics
ATOS
33 hedge funds and large institutions have $6.52M invested in Atossa Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 39 closing their positions.
25% more capital inflows, than outflows
Capital inflows: $3.13M | Capital outflows: $2.51M
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
2.62% less ownership
Funds ownership: 17.02% → 14.4% (-2.6%)
20% less call options, than puts
Call options by funds: $459K | Put options by funds: $572K
51% less funds holding
Funds holding: 67 → 33 (-34)
82% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$418K |
| 2 |
Morgan Stanley
New York
|
+$76.6K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.5K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$15.2K |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$618K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$382K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$246K |
| 4 |
Renaissance Technologies
New York
|
-$181K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$157K |
ATOS Hedge Fund Activity: Q1 2026 in Review
33 of the 8,214 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2026, worth a combined $6.52M — down 50% from $13M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ATOS and 7 opened new positions — a net loss of 32 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was UBS Group, adding an estimated $418K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $618K sold.
- 33 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2026, down from 67 in Q4 2025.
- Funds reported $6.52M of Atossa Therapeutics stock for Q1 2026, down 50% quarter-over-quarter.
- 7 funds opened new Atossa Therapeutics positions in Q1 2026 and 39 closed out, a net change of -32 holders.
- The largest Atossa Therapeutics buyer in Q1 2026 was UBS Group, an estimated $418K added.
- The largest Atossa Therapeutics seller in Q1 2026 was Jacobs Levy Equity Management, an estimated $618K sold.
Based on aggregated 13F filings for Q1 2026.